DFD-03 (0.1% Tazarotene), Twice-daily, Short-Contact Lotion Formulation, Showed Similar Pharmacokinetic Exposure to the Marketed Cream Product with Once-Daily Overnight Application. J of Skin [Internet]. 2017 Oct. 27 [cited 2026 May 2];1(3.1):s46. Available from: https://skin.dermsquared.com/skin/article/view/199